Compendia Bioscience and Althea Diagnostics Develop Breast Cancer Segregation Panel(TM) Assay as a Platform for Companion Diagnostic Development
Published: Dec 08, 2010
Compendia Bioscience will analyze the data generated by the assay and will perform correlation studies to end-points of interest — such as drug response. This will allow for development of multiple drug-specific companion diagnostics from a standardized platform.
The partnership leverages the unique expertise of each company. Compendia Bioscience is a recognized leader in the cancer genomics data collection, curation and analysis. Althea Diagnostics has a long pedigree in gene quantification from FFPE samples and is a leading provider of diagnostic development services for pharmaceutical companies. The companies have also announced that they plan to develop similar assays for other cancer disease types. The companies have begun development of a Colon Segregation Panel™ assay, which will be available in 2011.
About Compendia Bioscience, Inc.
Compendia Bioscience is dedicated to applying the global collection of cancer genomic data to impact patient treatment by enabling the discovery and development and better cancer diagnostics and treatments. www.compendiabio.com For additional information regarding this announcement, please contact:
Chief Business Officer, Compendia Bioscience Phone: (734) 945-6344 E-mail: firstname.lastname@example.org